Manifold Bio was founded with the core mission of revolutionizing drug development through high-throughput protein measurement technology. The company focuses on designing tissue-specific medicines in living systems by integrating high-throughput in-vivo studies with AI-guided protein design. Their primary offerings include a multiplexed protein measurement platform aimed at exponentially increasing measurement throughput at all stages of drug development, targeting the biopharmaceutical market.

Notable affiliated individuals and investors include prominent figures in biotechnology and venture capital. Manifold Bio has achieved significant milestones in optimizing tissue-specific drug delivery, leveraging AI to enhance therapeutic interventions. The company's innovative approach has garnered attention for its potential to transform the efficiency and specificity of drug development, making a substantial impact on the biopharmaceutical industry.